Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
5(100.0%)
5Total
Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06467435Phase 1Terminated

Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)

Role: collaborator

NCT07396818Phase 1Not Yet Recruiting

Kamlanoflast In Amyotrophic Lateral Sclerosis

Role: lead

NCT06164587Phase 1Active Not Recruiting

Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy

Role: collaborator

NCT06781255Phase 1Recruiting

Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)

Role: collaborator

NCT05699759Phase 1Completed

Safety and Effect of Intravitreal Injection of a Derivative of Nucleoside Reverse Transcriptase Inhibitor in Subjects with Diabetic Macular Edema

Role: collaborator

All 5 trials loaded